MOUNJARO™ ( Tirzepatide) was approved for medical use in the United States in May 2022 WEIGHT LOSS: (Not approved by FDA for weight loss) Eli Lilly and Company is finalizing an application to the U.S. Food and Drug Administration for fast-track approval to sell tirzepatide for chronic weight management. MOUNJARO™ is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated in adults for type 2 diabetes mellitus management. CONTRAINDICATIONS Personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2 Known serious all to tirzepatide or any of the excipients in MOUNJARO ...
This is a blog by Kaleem Mohammed, PhD, for those who want to understand little more about health conditions and medications. He is a community pharmacist and chronic disease educator for Salt Lake County Health dept. As an Asst. Prof at University of Utah, he taught pharmacology to MD, PA and PharmD students. His Hypoxia Inducible Factor-1 research has been cited by Drs. Gregg Samenza/EJ Corey (Nobel, 2019/1990)